Sagimet Biosciences, Inc. Class A(SGMT)
$11.41+0.52 (+4.78%)
SGMT
Sagimet Biosciences, Inc. Class A financials statements
$11.41
At close:+0.52 (+4.78%)
Want to see SGMT full AI Analyst Report?
Sagimet Biosciences, Inc. Class A (SGMT) Ratios
1,727 Followers
Sagimet Biosciences, Inc. Class A Ratios
SGMT's free cash flow for Q2 2026 was $-10.70M. For the 2026 fiscal year, SGMT's free cash flow was increased by $0.00 and operating cash flow was $-10.70M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 22.82 | 34.30 | 17.09 | 6.21 | 24.04 |
| Quick Ratio | 22.82 | 34.30 | 17.09 | 6.21 | 24.04 |
| Cash Ratio | 6.87 | 17.03 | 13.29 | 0.03 | 23.25 |
| Solvency Ratio | -10.01 | -10.23 | -4.93 | -0.14 | -0.11 |
| Operating Cash Flow Ratio | -8.95 | -9.53 | -4.20 | -4.64 | -8.90 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 111.30M | $ 148.32M | $ 90.99M | $ -187.19M | $ -158.63M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | -0.00 | -0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | -0.00 | -0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.05 | 1.03 | 1.06 | -0.18 | -0.37 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 |
| Net Debt to EBITDA | 0.68 | 1.66 | 2.44 | -0.00 | 2.38 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | -1537.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | -1537.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | -1537.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | -1393.80% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | -1393.80% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | -1393.80% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 89.72% | 83.68% | 90.68% | 98.21% | 103.05% |
| Return on Assets (ROA) | -43.82% | -28.43% | -28.82% | -92.33% | -41.40% |
| Return on Equity (ROE) | -45.82% | -29.25% | -30.61% | 16.31% | 15.44% |
| Return on Capital Employed (ROCE) | -51.08% | -34.95% | -33.76% | -111.90% | -41.91% |
| Return on Invested Capital (ROIC) | -51.04% | -34.93% | -33.73% | -111.37% | -41.82% |
| Return on Tangible Assets | -43.82% | -28.43% | -28.82% | -92.33% | -41.40% |
| Earnings Yield | -26.65% | -32.30% | -28.27% | -8.62% | -6.91% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 27.40 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.41 | -1.35 | -1.31 | -1.10 | -0.98 |
| Free Cash Flow Per Share | -1.41 | -1.35 | -1.31 | -1.10 | -0.98 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -585.26 | -544.04 | -365.63 | -116.07 | -62.39 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | -11.88 | 0.00 | 0.00 |
| Free Cash Flow Yield | -23.84% | -30.08% | -24.10% | -6.92% | -6.14% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -3.75 | -3.10 | -3.54 | -11.60 | -14.47 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 49.31 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 1.72 | 0.91 | 1.08 | -1.89 | -2.23 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -4.19 | -3.32 | -4.15 | -14.44 | -16.29 |
| Price-to-Operating Cash Flow Ratio | -4.19 | -3.32 | -4.15 | -14.44 | -16.29 |
| Price-to-Earnings Growth (PEG) Ratio | -0.42 | 0.59 | -0.33 | -0.46 | -0.13 |
| Enterprise Value Multiple | -3.07 | -1.43 | -0.77 | -11.39 | -12.53 |
| Enterprise Value | 156.54M | 65.32M | 23.54M | 353.73M | 297.29M |
| EV to EBITDA | -3.07 | -1.43 | -0.77 | -11.39 | -12.53 |
| EV to Sales | 0.00 | 0.00 | 11.77 | 0.00 | 0.00 |
| EV to Free Cash Flow | -3.43 | -1.54 | -0.99 | -14.44 | -13.69 |
| EV to Operating Cash Flow | -3.43 | -1.54 | -0.99 | -14.44 | -13.69 |
| Tangible Book Value Per Share | 3.44 | 4.97 | 5.01 | -8.43 | -7.14 |
| Shareholders’ Equity Per Share | 3.44 | 4.97 | 5.01 | -8.43 | -7.14 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.11 | 0.00 | 0.00 |
| Net Income Per Share | -1.58 | -1.45 | -1.53 | -1.38 | -1.10 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.91 | 0.98 | 1.03 |
| Research & Development to Revenue | 0.00 | 0.00 | 9.89 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 6.48 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 2.50 | 0.00 | 0.00 |
| Income Quality | 0.89 | 0.93 | 0.85 | 0.80 | 0.89 |
Currency in USD
